Abstract

Introduction: The S100 protein family plays an important role as biomarker in several types of tumors. One of the family members is the S100A12 protein, recently known as a new marker in tumorigenicity and gastric cancer research. Considering the diagnostic importance of S100A12 and the relatively high prevalence of gastric cancer in Iran, this study aimed at examining the expression of S100A12 in the tissues of such patients.

Method: The expression of S100A12 in 79 Gastric Cancer patients was examined using immunohistochemistry in tumor tissue cells, and 50 non-tumor samples were selected for comparison with tumor tissues. Data analysis was conducted using SPSS v16 and chi-square test with a confidence interval of 95 percent.

Results: The results showed that there was a significant difference between tumor tissues and non-tumor tissues with regard to the expression of S100A12 protein, with tumor cells showing significantly lower expression. Based on clinicopathologic results, S100A12 protein indicated a negative correlation with tumor dimensions, tumor invasion depth, metastasis stage of tumor, and no significant correlation with other clinicopathologic features, like age, sex and metastasis to lymph nodes.

Conclusion: The results showed that the low expression of S100A12 as a new marker was associated with tumor formation and Gastric Cancer progression.

Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. The international journal of biochemistry & cell biology. 2001;33[7]:637-68.

Chen H, Xu C, Qing’e Jin ZL. S100 protein family in human cancer. American journal of cancer research. 2014;4[2]:89.

Donato R, R Cannon B, Sorci G, Riuzzi F, Hsu K, J Weber D, et al. Functions of S100 proteins. Current molecular medicine. 2013;13[1]:24-57.

Zhang Q, Zhu M,Cheng W, Xing R, Li W, Zhao M, et al. Downregulation of 425G> A variant of calcium-binding protein S100A14 associated with poor differentiation and prognosis in gastric cancer. Journal of cancer research and clinical oncology. 2015;141[4]:691-703.

Ling Z, Li R. Clinicopathological and prognostic value of S100A4 expression in gastric cancer: a meta-analysis. 2014.

Wang H, Zhang Z, Li R, Ang KK, Zhang H, Caraway NP, et al. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. International journal of cancer. 2005;116[2]:285-90.

Missiaglia E, Blaveri E, Terris B, Wang YH, Costello E, Neoptolemos JP, et al. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. International journal of cancer. 2004;112[1]:100-12.

Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE [Receptor for Advanced Glycation Endproducts], RAGE ligands, and their role in cancer and inflammation. Journal of translational medicine. 2009;7[1]:17.

Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene. 2003;22[42]:6549.

Li D, Zeng Z, Yu T, Qin J, Wu J, Song J-C, et al. Expression and clinical implication of S100A12 in gastric carcinoma. Tumor Biology. 2016;37[5]:6551-9.

Hsu K, Champaiboon C, Guenther BD, Sorenson BS, Khammanivong A, Ross KF, et al. Anti-infective protective properties of S100 calgranulins. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry [Formerly Current MedicinalChemistry-Anti-Inflammatory and Anti-Allergy Agents]. 2009;8[4]:290-305.

Meijer B, Gearry R, Day A. The role of S100A12 as a systemic marker of inflammation. International journal of inflammation. 2012.

Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflammatory bowel diseases. 2014;20[4]:742-56.

Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflammatory bowel diseases. 2014;20[9]:1668-77.

Pac-Kozuchowska E, Krawiec P, Mroczkowska-Juchkiewicz A. Fecal lactoferrin in identifying and management of inflammatory bowel disease. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego. 2014;37[217]:61-4.

Geczy CL, Chung YM, Hiroshima Y. Calgranulins may contribute vascular protection in atherogenesis. Circulation Journal. 2014;78[2]:271-80.

Funk S, Mark R, Bayo P, Flechtenmacher C, Grabe N, Angel P, et al. High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma. International journal of cancer. 2015;136[9]:2037-46.

Thierolf M, Hagmann ML, Pfeffer M, Berntenis N, Wild N, Roeßler M, et al. Towards a comprehensive proteome of normal and malignant human colon tissue by 2‐D‐LC‐ESI‐MS and 2‐DE proteomics and identification of S100A12 as potential cancer biomarker. PROTEOMICS-Clinical Applications. 2008;2[1]:11-22.

Liu Y-F, Liu Q-Q, Wang X, Luo C-H. Clinical significance of S100A2 expression in gastric cancer. Tumor Biology. 2014;35[4]:3731-41.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61[2]:69-90.

Pantel K, Riethmüller G. Micrometastasis detection and treatment with monoclonal antibodies. Attempts to Understand Metastasis Formation III: Springer; 1996. p. 1-18.

Zhang J, Zhang K, Jiang X, Zhang J. S100A6 as a potential serum prognostic biomarker and therapeutic target in gastric cancer. Digestive diseases and sciences. 2014;59[9]:2136-44.

Wu C-W, Chi C-W, Lin W-c. Gastric cancer: prognostic and diagnostic advances. Expert reviews in molecular medicine. 2002;4[6]:1-12.

Fan B, Zhang L-H, Jia Y-n, Zhong X-Y, Liu Y-Q, Cheng X-J, et al. Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer. BMC cancer. 2012;12[1]:316.